Resources

In this blog, Richard Turner, Senior Managing Director at FTI Consulting, discusses how licence and collaboration agreements in life sciences can create significant tax consequences.

It’s been an energising week across the UK life sciences landscape, marked by major investment, important conversations and new opportunities for our community.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

In this blog, Jane Wall, Managing Director of the BioIndustry Association (BIA), reflects on a roundtable with the Milken Institute and Jill Biden.

In this guest blog, Hareklea Markides, Innovation Lead - Medicines Manufacturing at Innovate UK, reflects on the UK BioIndustry Association's (BIA) annual #bioProcessUK conference.

TechBio’s potential to both transform our sector and provide precision diagnosis and care to patients is well recognised, and TechBio Boost is playing a vital role in scaling companies in this space.

In this blog, Abby Clark, Manufacturing Programme Manager at BIA, highlights some of the key achievements of BIA and ABPI’s Medicines Manufacturing Industry Partnership (MMIP).

In this guest blog, BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, shares expert insight into the UK’s evolving R&D tax relief landscape for life sciences companies.

A bumper update today as we highlight the critical importance of building UK capability and innovation leadership as geopolitics continues to provide uncertainty.

What an incredible night! Last Thursday, we welcomed a record 780 of you to the Roundhouse for the 2026 BIA Gala Dinner. It was a powerful reminder of the strength, resilience and sheer brilliance of our community.

In this blog, Saqib Lal, Head of Content at BIA, reflects on a stellar Gala Dinner. He describes it as a moment to pause and recognise the extraordinary people who make the UK life sciences sector a global powerhouse. This year, as a record 780 guests gathered at the iconic Roundhouse for an evening that demonstrated renewed ambition and positivity. 

In this blog, Emily Klein, Senior Policy and Public Affairs Executive at BIA, explores the hidden, wide-ranging impacts and costs of rare diseases to society and the wider economy in the UK.

As 2026 shapes up to an unpredictable year, our policy experts have provided more grounding for what the life sciences sector should expect over the next 12 months. This is the second and final part of our 2026 outlook series. 

Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.

With a number of unprecedented leaks, speculation and media briefings indicating potential wide ranging and significant tax rises, in the end the 2025 Autumn Budget seemed to be one of restraint and headline rates remained untouched.

We’re excited to launch She Steers, NEDs in Biotech, a specialist Non-Executive Director (NED) board programme created for women across life sciences and biotech.

J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, explores Biosolutions, defining what they are and their potential to solve global challenges beyond health.

As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.

This week JPM kicks off in San Francisco with BIA hosting a UK Reception. A significant week for BIA too with the long-awaited announcement of our new CEO.